|
| Status |
Public on Mar 31, 2021 |
| Title |
Gut Microbe-Targeted Choline Trimethylamine Lyase Inhibitors Improves Obesity Via Rewiring of Host Circadian Rhythms. |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
The increasing prevalence of obesity and related metabolic disorders represents a growing public health concern. Despite advances in other areas of medicine, a safe and effective drug treatment for obesity has been elusive. Obesity has repeatedly been linked to reorganization of the gut microbiome 1-4 , yet to this point obesity therapeutics have been targeted exclusively toward the human host. Here we show that gut microbe-targeted inhibition of the metaorganismal trimethylamine N-oxide (TMAO) pathway protects mice against the metabolic disturbances associated with diet-induced obesity (DIO) or leptin deficiency (ob/ob). Selective small molecule inhibition of the gut microbial enzyme choline TMA-lyase (CutC) does not significantly reduce food intake, but instead is associated with beneficial remodeling of the gut microbiome, improvement in glucose tolerance, and enhanced energy expenditure. Leveraging untargeted metabolomics we discovered that CutC inhibition is associated with reorganization of host circadian control of both phosphatidylcholine and energy metabolism. Collectively, this study underscores the close relationship between microbe and host metabolism, and provides evidence that gut microbe-derived trimethylamine (TMA) is a key regulator of the host circadian clock. This work also demonstrates that gut microbe-targeted enzyme inhibitors can have profound effects on host energy metabolism, and have untapped potential as anti-obesity therapeutics.
|
| |
|
| Overall design |
All animals were on a 60% high fat diet leading into the study. One group (n=5) was maintained as vehicle cohort. The other group (n=6) was maintained on IMC (specific inhibitor of choline conversion to TMA). We analyzed n = 6 per Vehicle group, however one of the control samples did not meet QC standards and was dropped from the study.
|
| |
|
| Contributor(s) |
Brown JM, Schugar R, Gliniak C, Neumann C |
| Citation(s) |
35072627 |
| |
| Submission date |
Sep 14, 2020 |
| Last update date |
Feb 08, 2022 |
| Contact name |
Chase Neumann |
| E-mail(s) |
ckn12@case.edu
|
| Phone |
2164401104
|
| Organization name |
CCF
|
| Street address |
99089 Carnegie Ave
|
| City |
Cleveland |
| State/province |
OH |
| ZIP/Postal code |
44195 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL21103 |
Illumina HiSeq 4000 (Mus musculus) |
|
| Samples (11)
|
|
| Relations |
| BioProject |
PRJNA663343 |
| SRA |
SRP282353 |
Less...
More...